Redeye: Initiating coverage of Xspray Pharma

Redeye initiates analyst coverage of Xspray Pharma, a Swedish biopharma with a unique business model. Three product candidates are lined up to reach the market between 2020-2023, and it is our belief that Xspray can utilize their RightSize technology platform to become a niche generic player that can out-maneuver other market players. 

Fair value in our Base Case indicates about 80% upside from current share price. Read more and download the research report by Mathias Spinnars: https://goo.gl/TSPBjk

Start following Xspray Pharma at Redeye to instantly receive our latest analyst updates and comments.

This is a press release from Redeye - Research Powered Investment Banking. https://www.redeye.se/about/

Prenumerera